Product Development & Regulation Flashcards

A sponsor has successfully completed a Phase I trial for a new oncology drug, establishing its initial safety profile and identifying a maximum tolerated dose in healthy volunteers. What is the primary objective of the subsequent Phase II clinical trial?

Answer: To evaluate the drug's effectiveness for a specific cancer type in a well-defined patient group and to further assess its short-term safety and side effects.

Phase II trials are the first to test a new drug's efficacy in patients with the target disease or condition. After initial safety is established in Phase I, the goal of Phase II is to see if the drug works for its intended purpose in a limited patient group and to continue monitoring safety to determine a proper dose for larger studies.

Which of the following statements is most accurate regarding the Investigator's Brochure (IB)?

Answer: It is a comprehensive compilation of the clinical and nonclinical data on the investigational product known to date and is maintained by the sponsor.

According to ICH GCP guidelines, the Investigator's Brochure (IB) is a comprehensive document that summarizes the body of information known about an investigational product, including nonclinical and clinical data. The sponsor is responsible for creating it and keeping it up to date, with a review at least annually. The information must be presented in an objective, non-promotional manner.

A medical device company has developed a novel, implantable deep brain stimulation device for treating severe depression. This type of device is considered a significant risk. Before initiating a clinical trial to evaluate its safety and effectiveness, the sponsor must obtain which of the following from the FDA?

Answer: An Investigational Device Exemption (IDE).

An Investigational Device Exemption (IDE) allows an investigational device that poses a significant risk to be used in a clinical study to collect safety and effectiveness data. A 510(k) and a PMA are applications for marketing a device, not for conducting an investigational trial. An NDA is for drugs, not devices.

During a Phase I trial for a new antiviral agent, several participants are hospitalized with acute liver failure, an unexpected and severe adverse reaction. The FDA orders the sponsor to immediately stop dosing all participants and halt new enrollment. This regulatory action is called a:

Answer: Clinical Hold

A clinical hold is an order issued by the FDA to a sponsor to delay a proposed clinical investigation or to suspend an ongoing one. This action is taken if, among other reasons, human subjects are or would be exposed to an unreasonable and significant risk of illness or injury.

Before a sponsor can legally ship an investigational new drug across state lines to a clinical investigator to begin a study in humans, the sponsor must first submit which application to the FDA?

Answer: An Investigational New Drug (IND) application

A sponsor must submit an Investigational New Drug (IND) application to the FDA before beginning any clinical research in humans. The IND provides data from preclinical studies to show that the product is reasonably safe for initial testing in humans. The sponsor must wait 30 days after IND submission before initiating trials, during which the FDA reviews the application for safety.

By signing the FDA Form 1572, Statement of Investigator, a clinical investigator makes a binding commitment to the sponsor to perform which of the following actions?

Answer: Personally conduct or supervise the investigation and ensure that all study staff are informed about their obligations.

The FDA Form 1572 is a legally binding agreement between the investigator and the sponsor. By signing it, the investigator commits to personally conduct or supervise the study, follow the protocol, comply with all applicable regulations (including obtaining informed consent and IRB review), and ensure all assisting staff are properly informed of their duties.